Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Research & Development (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Research & Development for 9 consecutive years, with $42.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 2.1% to $42.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $167.3 million, a 29.68% decrease, with the full-year FY2025 number at $167.3 million, down 29.68% from a year prior.
  • Research & Development was $42.0 million for Q4 2025 at Rhythm Pharmaceuticals, down from $46.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $128.7 million in Q1 2024 to a low of $19.9 million in Q1 2021.
  • A 5-year average of $38.2 million and a median of $33.5 million in 2023 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 239.08% in 2024, then tumbled 71.26% in 2025.
  • Rhythm Pharmaceuticals' Research & Development stood at $31.6 million in 2021, then fell by 25.42% to $23.5 million in 2022, then increased by 26.94% to $29.9 million in 2023, then skyrocketed by 37.72% to $41.2 million in 2024, then grew by 2.1% to $42.0 million in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Research & Development are $42.0 million (Q4 2025), $46.0 million (Q3 2025), and $42.3 million (Q2 2025).